T. Rowe Price Associates
PROK icon

T. Rowe Price Associates’s ProKidney PROK Stock Holding History

T. Rowe Price Associates’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,108
Closed -$38K – 3130
2025
Q1 		$38K Buy
43,108
+2,630
+6% +$3.65K ﹤0.01% 2959
2024
Q4 		$69K Buy
40,478
+5,073
+14% +$9.15K ﹤0.01% 2892
2024
Q3 		$68K Buy
35,405
+16,211
+84% +$36.8K ﹤0.01% 2888
2024
Q2 		$48K Buy
19,194
+8,709
+83% +$23.4K ﹤0.01% 2861
2024
Q1 		$18K Hold
10,485
– – ﹤0.01% 2932
2023
Q4 		$19K Buy
+10,485
New +$22.5K ﹤0.01% 2875
2023
Q3 		– Sell
-12,501
Closed -$140K – 2907
2023
Q2 		$140K Buy
+12,501
New +$133K ﹤0.01% 2623

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BU
Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's PROK Position: Q2 2025 in Review

T. Rowe Price Associates sold out of ProKidney (PROK) in Q2 2025, closing a stake of 43,108 shares — an estimated $38K sold.

T. Rowe Price Associates first reported a position in PROK in Q2 2023 and held it in 7 quarters. The position peaked at $140K in Q2 2023. 56 funds tracked by Wall St. Rank hold PROK as of Q2 2025.

  • T. Rowe Price Associates reported no remaining ProKidney position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 43,108 ProKidney shares in Q2 2025, an estimated $38K.
  • T. Rowe Price Associates first reported a position in ProKidney in Q2 2023 and held it in 7 quarters.
  • T. Rowe Price Associates's ProKidney position peaked at $140K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held ProKidney as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.